GERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/
-- Precigen, Inc. (Nasdaq: PGEN), a
biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of
patients, today announced the Company will release fourth quarter
and full year 2020 financial results after the market closes on
Monday, March 1, 2021. The
Company will host a conference call that day at 4:30 PM ET to discuss financial results and
provide a general business update.
The conference call may be accessed by dialing 1-888-317-6003
(Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and
providing the number 9387943 to join the Precigen Conference Call.
Participants are asked to dial in 10-15 minutes in advance of the
scheduled call time to facilitate timely connection to the
call.
Helen Sabzevari, PhD, President
and CEO, will also present at the H.C. Wainwright Virtual Global
Life Sciences Conference and the on-demand webcast will be
available starting Tuesday, March 9,
2021 at 7:00 AM ET.
Participants may register and access the webcasts for both
events through Precigen's website in the Events & Presentations
section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated unique therapies toward clinical
proof-of-concept and commercialization. For more information about
Precigen, visit www.precigen.com or follow us on Twitter @Precigen
and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press
release are forward-looking statements. These forward-looking
statements are based upon the Company's current expectations and
projections about future events and generally relate to plans,
objectives, and expectations for the development of the Company's
business, including the timing and progress of preclinical studies,
clinical trials, discovery programs and related milestones, the
promise of the Company's portfolio of therapies, and in particular
its CAR-T and AdenoVerse therapies. Although management believes
that the plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties, including the
possibility that the timeline for the Company's clinical trials
might be impacted by the COVID-19 pandemic, and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor
Contact:
|
Media
Contact:
|
Steven
Harasym
|
Glenn
Silver
|
Vice President,
Investor Relations
|
Lazar-FINN
Partners
|
Tel: +1 (301)
556-9850
|
glenn.silver@finnpartners.com
|
investors@precigen.com
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/precigen-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-march-1st-301232765.html
SOURCE Precigen, Inc.